{"result": "(\"entity\"<|>AMERICAN DIABETES ASSOCIATION<|>ORGANIZATION<|>The American Diabetes Association is a leading organization focused on diabetes research, education, and advocacy, providing standards of medical care in diabetes management.)\n##\n(\"entity\"<|>DIABETES CARE<|>ORGANIZATION<|>Diabetes Care is a journal published by the American Diabetes Association that focuses on clinical research and practice in diabetes management.)\n##\n(\"entity\"<|>CLopidogrel<|>PERSON<|>Clopidogrel is an antiplatelet medication used in patients with cardiovascular disease, particularly those with documented allergy to aspirin.)\n##\n(\"entity\"<|>ACID ACETILSALICYLIC<|>PERSON<|>Acid acetilsalicylic, commonly known as aspirin, is used as a preventive treatment in patients with diabetes and a history of cardiovascular disease.)\n##\n(\"entity\"<|>METFORMIN<|>PERSON<|>Metformin is a medication used to treat type 2 diabetes by reducing hepatic glucose production and increasing insulin sensitivity.)\n##\n(\"entity\"<|>PIOGLITAZONE<|>PERSON<|>Pioglitazone is a medication that reduces insulin resistance and improves lipid profiles in patients with type 2 diabetes.)\n##\n(\"entity\"<|>SULFONYLUREAS<|>PERSON<|>Sulfonylureas are a class of medications that stimulate insulin secretion from pancreatic beta cells in the treatment of diabetes.)\n##\n(\"entity\"<|>GLINIDAS<|>PERSON<|>Glinidas are a class of medications that increase insulin secretion from pancreatic beta cells, with a short duration of action.)\n##\n(\"relationship\"<|>AMERICAN DIABETES ASSOCIATION<|>DIABETES CARE<|>The American Diabetes Association publishes the journal Diabetes Care, which provides clinical guidelines and research on diabetes management.<|>8)\n##\n(\"relationship\"<|>ACID ACETILSALICYLIC<|>CLOPIDOGREL<|>Clopidogrel is used as an alternative to acid acetilsalicylic for patients with cardiovascular disease who have an allergy to aspirin.<|>7)\n##\n(\"relationship\"<|>METFORMIN<|>SULFONYLUREAS<|>Both metformin and sulfonylureas are medications used in the management of type 2 diabetes, but they work through different mechanisms.<|>6)\n##\n(\"relationship\"<|>PIOGLITAZONE<|>METFORMIN<|>Pioglitazone and metformin are both used to treat type 2 diabetes, often in combination to improve glycemic control.<|>6)\n##\n(\"relationship\"<|>GLINIDAS<|>SULFONYLUREAS<|>Glinidas and sulfonylureas both stimulate insulin secretion from pancreatic beta cells, but glinidas have a shorter duration of action.<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Fogari R, Zoppi A, Malamani GD, Lazzari P, Albonico B, Corradi L. Urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus. Am J Hypertens. 1994;7(9 Pt 1):808-13.\n- Redon J, Liao Y, Lozano JV, Miralles A, Pascual JM, Cooper RS. Ambulatory blood pressure and microalbuminuria in essential hypertension: role of circadian variability. J Hypertens. 1994;12(8):947-53.\n- Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006;8(5):351-6; quiz 357-8. PubMed PMID: 16687944.\n\n## 58 Con respecto a la antiagregación en los pacientes con diabetes, es cierto que:\n\nA. El antiagregante de elección es el clopidogrel.\nB. Se ofrecerá tratamiento a los pacientes en prevención secundaria.\nC. La dosis correcta de ácido acetilsalicílico es de 250 mg en dosis única.\nD. Todas las respuestas anteriores son falsas.\n\n### COMENTARIO\n\nUse la terapia con ácido acetilsalicílico (75-162 mg/día) como una estrategia de prevención secundaria en las personas con diabetes y un historial de enfermedad cardiovascular aterosclerótica.\n\nPara pacientes con enfermedad cardiovascular aterosclerótica y alergia documentada al ácido acetilsalicílico, se debe usar clopidogrel (75 mg/día).\n\nLa terapia con ácido acetilsalicílico (75-162 mg/día) se puede considerar como una estrategia de prevención primaria en las personas con diabetes que tienen un mayor riesgo cardiovascular, después de una discusión con el paciente sobre los beneficios frente a un mayor riesgo de sangrado.\n\nReferencias:\n- American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103-23.\n\n## 59 Señale la afirmación falsa en relación con los efectos de los fármacos para el tratamiento de la DM2:\n\nA. La metformina inhibe la gluconeogénesis hepática.\nB. La pioglitazona reduce los triglicéridos.\nC. Las sulfonilureas actúan a través de la unión al receptor IRS-1 de la membrana plasmática de la célula β.\nD. Los inhibidores de DPP4 producen un aumento de GLP1 y GIP endógeno.\n\n### COMENTARIO\n\nLa metformina reduce la producción hepática de glucosa mediante la inhibición de la gluconeogénesis y la glucogenólisis al tiempo que aumenta la síntesis intracelular de glucógeno al actuar sobre la glucógeno sintetasa. En el músculo incrementa la sensibilidad a la insulina mejorando la captación de glucosa periférica y su utilización, ya que aumenta la capacidad de transporte de todos los tipos de transportadores de membrana de glucosa (GLUT) conocidos. Por último, retrasa la absorción intestinal de glucosa.\n\nLos efectos de la pioglitazona se producen a través de una reducción de la resistencia a la insulina, lo que conlleva un perfil lípido más favorable, con reducción de triglicéridos y aumento del colesterol HDL. Parece que la pioglitazona ejerce su acción al activar receptores nucleares específicos (receptor γ activado por un proliferador de peroxisoma), produciendo un aumento de la sensibilidad a la insulina de las células del hígado, del tejido adiposo y del músculo esquelético en animales. Se ha demostrado que el tratamiento con pioglitazona reduce la producción de glucosa hepática y aumenta la utilización de glucosa periférica en casos de resistencia a la insulina.\n\nTanto las sulfonilureas como las glinidas basan su mecanismo de acción en un aumento de la secreción de insulina por las células β. La secreción de insulina está regulada por los canales de potasio dependientes de ATP, localizados en la membrana de la célula β. La unión de sulfonilureas y glinidas en distintos puntos a este canal de potasio (se une a un receptor propio denominado SUR-1) induce su cierre y una despolarización de la célula β, que origina un incremento en la entrada de calcio en la célula y, como consecuencia, la liberación de insulina por exocitosis. La diferencia fundamental entre ambos grupos, sulfonilureas y glinidas, está en la duración corta de acción que presentan las glinidas, lo que limita su acción hipoglucemiante a la comida en la cual se administró el fármaco. Además de este mecanismo de acción principal, se han descrito otros efectos extrapancreáticos.\n---\nDI\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}